Other languages Aridis Pharmaceuticals, Inc.

Equities

ARDS

US0403341045

Market Closed - OTC Markets Other stock markets 02:49:43 2024-05-31 pm EDT			5-day change	1st Jan Change
0.0625 ^USD	+4.17%		+5.93%	-10.84%

2023	Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	Certain Options of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024	Dec. 15
Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 03
Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update	Nov. 03
Certain Options of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.	23-09-15
Certain Warrants of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.	23-09-15
Certain Pre-Funded Warrant of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.	23-09-15
Certain Common Stock of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.	23-09-15
Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-09-14
Aridis Pharmaceuticals : Termination of Material Agreement - Form 8-K	23-08-25
Aridis Pharmaceuticals, Inc. Announces Resignation as Chief Financial Officer	23-08-09
Aridis Pharmaceuticals Announces $2 Million Offering	23-08-02
CapitalGainsReport Penny Stock Bounce List: EPAZ, ARDS, FRTX, GNPX	23-07-24
Aridis Pharmaceuticals, Inc.(OTCPK:ARDS) dropped from S&P TMI Index	23-07-21
Aridis Pharmaceuticals : Accelaration/Increase of Financial Obligation - Form 8-K	23-07-20
Sector Update: Health Care Stocks Steady Premarket Tuesday	23-07-18
Aridis Pharmaceuticals, European Regulator Agree on Pneumonia Phase 3 Study Parameters; Shares Jump Premarket	23-07-18
Aridis Pharmaceuticals, Inc.(OTCPK:ARDS) dropped from NASDAQ Composite Index	23-07-18
Aridis Pharmaceuticals Reaches Agreement for Phase 3 Study of Pneumonia Treatment in Europe; Shares Jump After Hours	23-07-17
Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301	23-07-17
Aridis Receives Agreement from the European Medicines Agency on the Clinical Study Design and A Single Confirmatory Phase 3 Study of AR-301	23-07-17

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Aridis Pharmaceuticals, Inc.

Equities

ARDS

US0403341045

Other languages

Filters